News
-
-
-
PRESS RELEASE
Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
Real-world comparison shows Beyfortus and RSVpreF immunization programs reduce infant RSV hospitalizations in Spain and UK. Beyfortus provides sustained protection against RSV with high efficacy and safety profile -
-
PRESS RELEASE
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
Sanofi acquires Vigil Neuroscience to enhance neurology pipeline with an investigational medicine for Alzheimer's disease. The acquisition includes VG-3927, a small molecule TREM2 agonist -
-
-
PRESS RELEASE
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creating global consumer healthcare leader. Sanofi's sale of a 50.0% stake to CD&R marks a strategic move with total net cash proceeds of around €10 billion -
-
PRESS RELEASE
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 study in NEJM shows delayed disability progression in multiple sclerosis. Potential first therapy targeting immunologic drivers. US priority review ongoing
